Immunologic research
Cure8 research brief
Why This Matters
People with CGD commonly have liver involvement and some develop IBD-like intestinal disease; recognizing and monitoring these complications may affect care and outcomes.
The study suggests that higher ALT at diagnosis might signal increased mortality risk, indicating liver tests at diagnosis could be informative, although this requires confirmation.
Who Should Pay Attention
Clinicians who manage CGD (immunologists, hepatologists, gastroenterologists), researchers studying CGD and immune-related liver/GI disease, pediatric patients with CGD and their caregivers.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper highlights that liver disease is a frequent and important contributor to morbidity in CGD and that IBD-like GI disease can occur in a subset of patients. The analysis suggests baseline and ongoing liver function tests may have prognostic value, but the association with mortality was exploratory and needs confirmation in larger prospective studies.
Clinical implications: Clinicians caring for people with CGD should be aware of the high prevalence of hepatic manifestations and monitor liver function and growth in children; GI symptoms such as diarrhea, bleeding, and abdominal pain warrant evaluation for IBD and other CGD-related GI pathology.
Research implications: Findings point to the need for larger, prospective studies to validate ALT as a prognostic biomarker and to better define mechanisms linking immune dysfunction in CGD with hepatic and intestinal pathology.
Keep In Mind
This is a retrospective, single-center cohort spanning decades; findings (including the ALT–mortality link) are exploratory and need confirmation in larger, prospective cohorts. CGD is distinct from common IBD and management and risks may differ.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationImmunologic research
AuthorsZehra Genç Ozbay, Saliha Esenboga, Elif Soyak Aytekin +8 more
InstitutionDivision of Pediatric Immunology, Department of Pediatrics, Hacettepe University Medical School, Ankara, Turkey.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 21, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declarations. Ethics approval and consent to participate: This study was approved by the Hacettepe University Health Sciences Research Ethics Committee (approval number: 2026/01–38; research number: SBA 26/040; approval date: January 6, 2026). The study was conducted in accordance with the Declaration of Helsinki. Due to the retrospective nature of the study, the requirement for informed consent was waived by the ethics committee. Conflict of interest: The authors declare no conflict of interest. Competing interests: The authors declare no competing interests. Clinical Trial Number: Not applicable.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
What Are the Symptoms of Crohn’s Disease?
Knowing the range of Crohn’s symptoms helps you recognize when to seek care, track disease patterns, and explain concerns to your clinician. The article highlights location-based differences and serious complications...
Crohn’s Disease: What It Is, Why It Happens, and How It Affects You
This article gives a clear, patient-friendly overview of Crohn’s disease: what it is, common symptoms and complications, likely causes, and how doctors diagnose it. That context can help people recognize when to seek...
Crohn’s Disease: Is It in Your Genes?
Genetics can influence Crohn’s disease risk; knowing about risk genes and testing options may help people with a family history understand why disease runs in families and what testing can — and cannot — tell you. The...